VP16 and TBI as conditioning regimen for allogeneic BMT in patients with high risk and relapsed ALL and NHL.
Schwerdtfeger
R
R
UKRV Charlottenburg, Berlin, FRG.
Schmid
H
H
Baurmann
H
H
Kleiner
S
S
Zeiler
T
T
Henze
G
G
Siegert
W
W
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000601:surgery*; D012074:Remission Induction; D012086:Reoperation; D012307:Risk Factors; D014916:Whole-Body Irradiation / Q000009:adverse effects
D005047:Etoposide